Literature DB >> 8575187

Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eyedrops.

J Shimazaki1, H Saito, H Y Yang, I Toda, H Fujishima, K Tsubota.   

Abstract

Association between the use of diclofenac sodium (DfNa) eyedrops and the development of a postkeratoplasty persistent epithelial defect (PED) of the cornea were studied. In 100 consecutive patients undergoing penetrating keratoplasty who had no limbal or conjunctival epithelial abnormalities, 12 (12.0%) developed PED (persistence of epithelial defect for > 8 days after keratoplasty) postoperatively. The use of DfNa eyedrops correlated significantly with the development of PED (p = 0.0001, chi-square test). DfNa eyedrops were used in 19 eyes postoperatively, eight of which (42.1%) showed signs of PED. The type of preservation media, preservation time, indications for keratoplasty, or the surgical procedures performed did not correlate with the development of PED. These results indicate that DfNa eyedrops are toxic to the corneal epithelium postkeratoplasty. The eyedrops should be used with great care in patients with disorders of the corneal epithelium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8575187

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  11 in total

1.  Topical non-steroidal anti-inflammatory drugs for the treatment of cystoid macular edema post Descemet's stripping automated endothelial keratoplasty.

Authors:  Koji Kitazawa; Kanae Kayukawa; Koichi Wakimasu; Tsutomu Inatomi; Osamu Hieda; Kazuhiko Mori; Chie Sotozono; Shigeru Kinoshita
Journal:  Jpn J Ophthalmol       Date:  2018-09-25       Impact factor: 2.447

2.  Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs.

Authors:  A J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  2001

Review 3.  Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review.

Authors:  Bruce I Gaynes; Richard Fiscella
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  Cataract surgery and nonsteroidal antiinflammatory drugs.

Authors:  Richard S Hoffman; Rosa Braga-Mele; Kendall Donaldson; Geoffrey Emerick; Bonnie Henderson; Malik Kahook; Nick Mamalis; Kevin M Miller; Tony Realini; Neal H Shorstein; Richard K Stiverson; Barbara Wirostko
Journal:  J Cataract Refract Surg       Date:  2016-09       Impact factor: 3.351

Review 5.  The role of NSAIDs in the management of postoperative ophthalmic inflammation.

Authors:  Joseph Colin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs.

Authors:  Keping Xu; Mark McDermott; Linda Villanueva; Rhett M Schiffman; David A Hollander
Journal:  Clin Ophthalmol       Date:  2011-02-28

7.  Different cellular effects of four anti-inflammatory eye drops on human corneal epithelial cells: independent in active components.

Authors:  Mingli Qu; Yao Wang; Lingling Yang; Qingjun Zhou
Journal:  Mol Vis       Date:  2011-12-06       Impact factor: 2.367

8.  Comparison of effect of nepafenac and diclofenac ophthalmic solutions on cornea, tear film, and ocular surface after cataract surgery: the results of a randomized trial.

Authors:  Atsushi Kawahara; Tsugiaki Utsunomiya; Yuji Kato; Yoshinori Takayanagi
Journal:  Clin Ophthalmol       Date:  2016-03-04

9.  Single subconjunctival injection formulation using sol-gel mesoporous silica as a controlled release system for drop-free post-cataract surgery care.

Authors:  Yaoyao Sun; Kristyn Huffman; William R Freeman; Lingyun Cheng
Journal:  J Cataract Refract Surg       Date:  2020-11       Impact factor: 3.528

10.  Unique circumferential peripheral keratitis in relapsing polychondritis: A case report.

Authors:  Naohiro Motozawa; Takahiro Nakamura; Seiji Takagi; Masashi Fujihara; Yasuhiko Hirami; Kazuhiro Ishida; Chie Sotozono; Yasuo Kurimoto
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.